Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FATE
stocks logo

FATE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.20M
-35.58%
-0.274
-37.63%
874.10K
-46.34%
-0.282
-11.72%
874.10K
-54.16%
-0.286
-1.29%
Estimates Revision
The market is revising Downward the revenue expectations for Fate Therapeutics, Inc. (FATE) for FY2025, with the revenue forecasts being adjusted by -10.28% over the past three months. During the same period, the stock price has changed by 8.91%.
Revenue Estimates for FY2025
Revise Downward
down Image
-10.28%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.66%
In Past 3 Month
Stock Price
Go Up
up Image
+8.91%
In Past 3 Month
Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is 5.29 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is 5.29 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 1.100
sliders
Low
2.00
Averages
5.29
High
8.00
Current: 1.100
sliders
Low
2.00
Averages
5.29
High
8.00
H.C. Wainwright
Robert Burns
Neutral -> Buy
upgrade
$5
2025-10-31
Reason
H.C. Wainwright
Robert Burns
Price Target
$5
2025-10-31
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics to Buy from Neutral with a $5 price target. The firm views the early results results from Fate's FT819 in 10 heavily pretreated systemic lupus erythematosus patients as "encouraging." The firm cites the results and the stock's valuation for the upgrade.
Wedbush
Martin Fan
Neutral
to
Outperform
upgrade
$5 -> $7
2025-10-27
Reason
Wedbush
Martin Fan
Price Target
$5 -> $7
2025-10-27
upgrade
Neutral
to
Outperform
Reason
As previously reported, Wedbush analyst Martin Fan upgraded Fate Therapeutics to Outperform from Neutral with a price target of $7, up from $5. The firm sees promise for lead program FT819 with increasing evidence for durable response, high patient accessibility, and positive regulatory engagement. Based on updated results at ACR and an approaching pivotal trial in lupus, Wedbush is moving from the sidelines on Fate shares and now recommends them to investors. The firm sees upside into ASH and would be a buyer ahead of follow-up at ASH and further clinical/regulatory catalysts.
Wedbush
Neutral -> Outperform
upgrade
$5 -> $7
2025-10-27
Reason
Wedbush
Price Target
$5 -> $7
2025-10-27
upgrade
Neutral -> Outperform
Reason
Wedbush upgraded Fate Therapeutics to Outperform from Neutral with a price target of $7, up from $5.
Wells Fargo
Equal Weight
downgrade
$4
2025-08-13
Reason
Wells Fargo
Price Target
$4
2025-08-13
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Fate Therapeutics to $2.50 from $4 and keeps an Equal Weight rating on the shares. The firm highlights new measures implemented by Fate to extend cash runway, including seeking partnership for the CAR NK program and a 12% workforce reduction. With runway now extended through year-end 2027, Wells sees additional CAR T SLE data and regulatory alignment as next focus.
Barclays
Overweight
to
NULL
downgrade
$10 -> $2
2025-05-14
Reason
Barclays
Price Target
$10 -> $2
2025-05-14
downgrade
Overweight
to
NULL
Reason
Baird
Neutral
downgrade
$5 -> $4
2025-05-14
Reason
Baird
Price Target
$5 -> $4
2025-05-14
downgrade
Neutral
Reason
Baird lowered the firm's price target on Fate Therapeutics to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fate Therapeutics Inc (FATE.O) is -0.97, compared to its 5-year average forward P/E of -10.47. For a more detailed relative valuation and DCF analysis to assess Fate Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.47
Current PE
-0.97
Overvalued PE
3.73
Undervalued PE
-24.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.14
Undervalued EV/EBITDA
-19.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
78.01
Current PS
0.00
Overvalued PS
149.27
Undervalued PS
6.76
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

FATE News & Events

Events Timeline

(ET)
2025-11-13
08:32:44
Fate Therapeutics announces Q3 earnings per share of 27 cents, below consensus estimate of 28 cents.
select
2025-10-14 (ET)
2025-10-14
08:11:51
Fate Therapeutics names Adawi as Chief Financial Officer
select
2025-08-12 (ET)
2025-08-12
16:12:19
Fate Therapeutics reports Q2 EPS (29c), consensus (34c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
10-27Benzinga
Needham Maintains Hold Rating on Fate Therapeutics

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences to improve their market performance.

  • Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.

[object Object]
Preview
9.0
10-26Newsfilter
Fate Therapeutics Unveils New Clinical Findings at ACR Convergence 2025 Highlighting Immune Remodeling and Lasting Responses in Systemic Lupus Erythematosus Patients Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

  • Clinical Trial Overview: Fate Therapeutics is conducting a Phase 1 clinical trial of FT819, an off-the-shelf CAR T-cell therapy, for patients with moderate-to-severe systemic lupus erythematosus (SLE), showing promising results with significant reductions in disease activity and favorable safety profiles.

  • Patient Outcomes: Among the first 10 patients treated, those surpassing the 3-month evaluation point demonstrated notable improvements in SLE Disease Activity Index scores, with some achieving complete renal response and sustained remission.

  • Safety and Administration: The treatment exhibited a favorable safety profile, with no dose-limiting toxicities and low-grade cytokine release syndrome, supporting the potential for same-day discharge after treatment, enhancing patient accessibility.

  • Future Directions: The company plans to expand its clinical program to include additional autoimmune diseases and is working with the FDA to design a registrational study, aiming to initiate a pivotal study in 2026.

[object Object]
Preview
9.0
08-15Newsfilter
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

  • Impact of Federal Budget Cuts on Cancer Research: Federal budget cuts have pressured cancer research in the U.S., but private investments are compensating, with oncology ventures securing significant funding. The Senate's restoration of $15 million for the Pancreatic Cancer Research Program highlights the fragility of public support amidst these challenges.

  • Oncolytics Biotech Inc.'s Progress: Oncolytics Biotech is advancing its flagship asset, pelareorep, into a critical trial phase for treating metastatic pancreatic ductal adenocarcinoma, demonstrating promising survival rates and receiving FDA designations that could expedite development and regulatory approval.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fate Therapeutics Inc (FATE) stock price today?

The current price of FATE is 1.1 USD — it has increased 1.85 % in the last trading day.

arrow icon

What is Fate Therapeutics Inc (FATE)'s business?

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

arrow icon

What is the price predicton of FATE Stock?

Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is 5.29 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fate Therapeutics Inc (FATE)'s revenue for the last quarter?

Fate Therapeutics Inc revenue for the last quarter amounts to 1.74M USD, decreased -43.36 % YoY.

arrow icon

What is Fate Therapeutics Inc (FATE)'s earnings per share (EPS) for the last quarter?

Fate Therapeutics Inc. EPS for the last quarter amounts to -0.27 USD, decreased -32.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fate Therapeutics Inc (FATE)'s fundamentals?

The market is revising Downward the revenue expectations for Fate Therapeutics, Inc. (FATE) for FY2025, with the revenue forecasts being adjusted by -10.28% over the past three months. During the same period, the stock price has changed by 8.91%.
arrow icon

How many employees does Fate Therapeutics Inc (FATE). have?

Fate Therapeutics Inc (FATE) has 181 emplpoyees as of December 05 2025.

arrow icon

What is Fate Therapeutics Inc (FATE) market cap?

Today FATE has the market capitalization of 128.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free